Investors

Home / Investors / Overview

Company Information

CymaBay Therapeutics (Nasdaq: CBAY)

We are a clinical-stage biopharmaceutical company focused on developing and providing access to innovative therapies for patients with liver and other chronic diseases with high unmet medical need. We are evaluating seladelpar in primary biliary cholangitis (PBC). The PBC program is on hold. We also have two product programs in earlier development that feature unique mechanisms of action and have potential in liver and chronic diseases.

Stock Information


Last Change Volume

Shares Outstanding: 10,064,495
(as of March 3, 2014)

Company Information

CymaBay Therapeutics
7575 Gateway Blvd
Suite 110
Newark, CA 94560

Investor Relations

Sujal Shah
(510) 293-8800
investors@cymabay.com

Recent News

19Jun

CymaBay Therapeutics Presents Data at Digestive Disease Week 2020 Online Education

5Jun

Notice of Change of Location of Annual Meeting of Stockholders to be Held on June 23, 2020

11May

CymaBay Reports First Quarter 2020 Financial Results and Provides Corporate Update

Q1 2020 Quarterly Results